A recent landmark—the first personalized CRISPR-based therapy delivered via lipid nanoparticles to treat a newborn with severe CPS1 deficiency—demonstrates how precision gene editing can be rapidly tailored to individual genetic conditions. This evidence concerns the gene CPS1 and hyperinsulinemic hypoglycemia, familial, 4.